Response to the numbering of seizure types
Robert S Fisher, J Helen Cross, Carol D'Souza, Jacqueline A French, Sheryl Haut, Norimichi Higurashi, Edouard Hirsch, Floor E Jansen, Lieven Lagae, Solomon L Moshe, Saul R Korey, Dominick P Purpura, Jukka Peltola, Eliane Roulet Perez, Ingrid E Scheffer, Andreas Schulze-Bonhage, Ernest Somerville, Michael Sperling, Elza Marcia Yacubian, Sameer M Zuberi
Epilepsia | WILEY | Published : 2017
Dr. Fisher has stock options from Avails Pharmaceuticals, Cerebral Therapeutics, Applied Neurometrics, Zeto, and SmartMonitor, and research grants from Medtronic. J. A. French discloses support via The Epilepsy Study Consortium, which pays Dr French's university employer for her consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert, Eisai, Georgia Regents University, GW Pharma, Marathon, Marinus, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Takeda, Turing, UCB Inc., Ultragenyx, Upsher Smith, Xenon Pharmaceuticals, Zynerba grants, and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, and the Epilepsy Study Consortium. She is on the editorial board of Lancet Neurology, Neurology Today and Epileptic Disorders, and was an Associate Editor of Epilepsia, for which she received a fee. Dr. Moshe receives from Elsevier annual compensation for his work as Associate Editor in Neurobiology of Disease and royalties from two books he coedited. He received a consultant's fee from Lundbeck, Eisai, and UCB. The remaining authors listed no disclosures relevant to the classification of seizure types. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.